Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes
Detailed Imeglimin Phase 3 TIMES 1 results to be presented at EASD; session chaired by Ralph DeFronzo, M.D., leading academic diabetes expert LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL –…
Read this Press Release: Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of DiabetesPoxel Announces Participation at the H.C. Wainwright 21st Annual Global Investment Conference
LYON, France--(BUSINESS WIRE)-- POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Announces Participation at the H.C. Wainwright 21st Annual Global Investment ConferencePoxel Reports Financial Results for First Half 2019 and Provides Corporate Update
Positive Phase 3 top-line results were reported for Imeglimin TIMES 1 and TIMES 3 16-week portion of the trial for the treatment of type 2 diabetes in Japan; Results from TIMES 2 and TIMES 3 36-week open label…
Read this Press Release: Poxel Reports Financial Results for First Half 2019 and Provides Corporate Update
Upcoming Events
55th Annual Meeting of the European Association for the Study of Diabetes
Licensing Executives Society (LES) 2019 Annual Meeting
BioNetwork Partnering Summit
Bio-Europe
Jefferies Global Healthcare Conference
World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease
